Tryptophan

A urine tryptophan result depends on what reaches your kidneys and how much they return to your blood. Urinary amino acid testing has a clinical role in investigating unusual amino acid loss. Using this individual measurement to predict heart disease, diabetes, or healthy aging remains exploratory.

The distinction matters when you're holding a result. A laboratory can measure a compound accurately without knowing whether changing that number improves your health. There is no established urinary tryptophan target for longevity or cardiovascular prevention.

What This Test Measures

Tryptophan is an essential amino acid. Amino acids are the building blocks of proteins. Your body cannot make tryptophan from scratch, so you need a dietary supply, though it also recycles tryptophan when existing proteins are broken down.

Most circulating tryptophan is attached to albumin. The unattached portion can pass through the kidney's filters, but the kidney normally reabsorbs most of what is filtered. The amount remaining in urine therefore depends on both the circulating supply and kidney handling. It is not a direct measure of your body's tryptophan stores or the amount available to your brain.

• A major breakdown route converts tryptophan into kynurenine and then other compounds, some of which contribute to vitamin B3 production. This is the kynurenine pathway.
• A smaller share supports serotonin production. Some serotonin is then converted into melatonin.
• Gut bacteria can convert tryptophan into indoles and related compounds. These are separate molecules from the tryptophan measured by this test.

This test uses liquid chromatography mass spectrometry, abbreviated LC-MS, to quantify tryptophan in urine. The instrument separates compounds and detects their characteristic mass signals. It reports a numerical result in mg/g. It does not measure kynurenine, serotonin, or the balance between these routes.

A Clinical Role in Amino Acid Loss

Urinary tryptophan can contribute to an evaluation for Hartnup disorder. This inherited condition affects the intestinal absorption and kidney reabsorption of several amino acids. Many affected people have no symptoms, while some develop a sun-sensitive rash or problems with coordination. Diagnosis depends on the broader amino acid pattern and clinical findings; an isolated tryptophan result is insufficient.

Heart Disease Research

A Shanghai study compared 275 adults who later developed coronary heart disease with 275 matched adults who did not. Researchers measured stored spot urine samples using LC-MS and adjusted the measurements for urine creatinine. After accounting for several established risk factors, people in the highest quarter of urinary tryptophan had about twice the odds of coronary heart disease as those in the lowest quarter. Among participants with abnormal blood lipids, the estimate was nearly four times the odds.

These are associations from a single observational study that examined many urinary compounds. They support further investigation, but do not establish urinary tryptophan as a reliable way to estimate your individual heart risk. The study also did not show that lowering urinary tryptophan prevents heart disease.

What the Kynurenine-to-Tryptophan Ratio Adds

Some of the stronger outcome research concerns the urinary kynurenine-to-tryptophan ratio. This compares two compounds and is a different measurement from tryptophan alone. Researchers use it to study tryptophan breakdown and immune activity, but kidney handling also affects the ratio.

Among about 3,200 Norwegian adults undergoing coronary angiography for suspected heart disease, a higher urinary ratio was associated with subsequent coronary events, heart attacks, and death over roughly five years. It was not associated with ischemic stroke. The urinary compounds were measured using gas chromatography tandem mass spectrometry, or GC-MS/MS, rather than this test's LC-MS method. The findings concern that research ratio and do not establish an interpretation for a standalone result in mg/g.

Type 2 Diabetes

Another analysis of the same Norwegian angiography cohort followed patients with suspected heart disease who did not have diabetes, for a median of 7.6 years. Among the 2,263 participants who provided urine samples, those in the highest quarter of the urinary kynurenine-to-tryptophan ratio had a little more than twice the risk of developing type 2 diabetes as those in the lowest quarter, after adjustment for other risk factors. This study also used GC-MS/MS for urine measurements, and its participants were not drawn from the general population.

Urinary tryptophan itself, adjusted for creatinine, was not associated with later diabetes in that study. The plasma ratio was also not predictive. A separate analysis within the PREDIMED diet trial found that higher baseline plasma tryptophan was associated with a higher risk of developing type 2 diabetes, so blood tryptophan findings point in a different direction from the urine results. These results do not establish a high urinary tryptophan result as an early sign of insulin resistance.

Why High and Low Results Are Hard to Interpret

Inflammation can accelerate tryptophan breakdown, but the direction of the urine result also depends on kidney function. In hospitalized people with COVID-19, researchers found increased urinary tryptophan as well as increased kynurenine-pathway products. The study linked the rise in urinary tryptophan to altered kidney reabsorption, while the kynurenine-pathway increase tracked with inflammation. A low urine result cannot establish that inflammation is consuming tryptophan, and a high result cannot establish that breakdown has slowed.

Gut, Brain, and Development Studies

Most studies in these areas compared people who already had a condition with a comparison group. Such studies can identify differences, but they cannot establish that the urine findings preceded the condition or that the same measurements can diagnose it.

• Autism: studies in children have reported differences in urinary tryptophan-related compounds and broader amino acid patterns. Results from panels of bacterial products cannot be assigned to urinary tryptophan alone.
• Parkinson's disease: an LC-MS/MS study of 41 people with Parkinson's disease and 20 controls found no significant difference in urinary tryptophan. Of the compounds examined, only indole-3-acetic acid differed significantly.
• Irritable bowel syndrome: one study found higher urinary serotonin breakdown products in the diarrhea group and higher kynurenine-pathway products in the constipation group. These product concentrations do not directly measure how quickly tryptophan moves through either route.
• Small intestinal bacterial overgrowth with depressive symptoms: a small study found differences in urinary kynurenine-pathway products. It did not establish urinary tryptophan alone as a diagnostic test for bacterial overgrowth or depression.

These studies do not establish a urinary tryptophan pattern that identifies the cause of ongoing gut symptoms, autism, or Parkinson's disease.

Kidney Transplant Outcomes

In 561 kidney transplant recipients followed for a median of seven years, urinary tryptophan and the measured urinary kynurenine-pathway compounds were not associated with graft failure or death. Some serum measurements were associated with those outcomes. This is another reason to keep blood and urine findings separate.

When Results Can Be Misleading

• Kidney handling: changes in filtration or reabsorption can alter urinary tryptophan independently of dietary intake. Kidney disease does not produce one predictable direction of change in every urinary amino acid.
• Urine concentration: dilution affects uncorrected concentrations. If the result is normalized to creatinine, that adjustment reduces dilution effects but introduces dependence on creatinine excretion, which also varies.
• Illness and pregnancy: acute illness can alter both tryptophan metabolism and kidney handling. A study of normal pregnancy also found changes in urinary tryptophan and kynurenine, so a change need not indicate disease.
• Diet, supplements, and medicines: these belong in the interpretation history. Findings about blood tryptophan or urinary breakdown products do not establish how much they change this particular urine measurement.
• Sample handling: collection timing, storage, and the laboratory's preparation procedures can affect comparability. Stability findings from one research protocol do not establish handling requirements for every commercial assay.

LC-MS also has its own sources of error. Other compounds in urine can suppress or enhance the signal, and substances that are not adequately separated can interfere with identification. Validated sample preparation, calibration, and suitable internal standards help control these problems. LC-MS results are not automatically interchangeable across laboratories.

What a Trend Can Establish

In a small study, 12 healthy adults provided first-morning urine samples weekly for ten weeks. The measured amino acids varied within individuals as well as between people. The published variability estimates covered many amino acids; they do not define a universal day-to-day allowance for urinary tryptophan.

Repeated measurements under comparable conditions can help establish whether an unexpected result persists. Even a reproducible change does not show that a supplement is helping, that inflammation has improved, or that future disease risk has fallen. Those interpretations require evidence beyond the trend itself.